Targeting cells which were dependent on GLUT3 by interfering with integrin and PAK4-YAP/TAZ signaling reduced GLUT3 expression and tumor cell viability, introducing a novel approach to treat this aggressive tumor type (41). Here, PAK4 is linked to neoplasm.